ライフサイエンスコーパス: therapy for

1 term responses to proteasome inhibitor-based therapy for 4 rejection phenotypes and to determine fact

2 pies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure we

3 ystemic corticosteroids are the mainstays of therapy for acute events.

4 e-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60).

5 The benefit of intravenous thrombolytic therapy for acute ischemic stroke is time dependent.

6 ligomerization and development of IAPP based therapies for AD and T2D.

7 No current therapy for AD is disease-modifying.

8 NIFICANCE STATEMENT The development of novel therapies for adult-onset neurodegenerative disease has

9 nd stratified by number of previous systemic therapies for advanced breast cancer and measurable vers

10 eviously received at least two HER2-targeted therapies for advanced disease.

11 ed controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care op

12 od and Drug Administration-approved targeted therapy for advanced MCC.

13 proach may lead to a novel, mechanism-guided therapy for AF.

14 e associated with outcome after endovascular therapy for AIS.

15 that empiric reductions in immunosuppressive therapy for all kidney transplant recipients with active

16 e crucial in devising appropriately targeted therapies for allergic diseases.

17 Development of tau-based therapies for Alzheimer's disease requires an understand

18 methods is essential to develop a successful therapy for Alzheimer's Disease.

19 A, a CDK inhibitor, as a potential targeted therapy for AML patients with an MLL rearrangement and a

20 ey are unready to quit, and using controller therapy for an extended treatment duration greater than

21 y the symbiotic quest of cardiac imaging and therapy for an increasing implementation of molecule-tar

22 noted following prolonged topical minoxidil therapy for androgenic alopecia.

23 less attention as an alternative cell-based therapy for animals or even humans.

24 red phase 2/3 clinical trials for adjunctive therapies for antidepressant partial- and non-responders

25 tifying optimal combinations of immune-based therapies for any given patient.

26 Gly203Ser, and present a safe, preventative therapy for associated cardiomyopathy.

27 beta2AR) agonists are a mainstay of clinical therapy for asthma and provide bronchorelaxation upon in

28 ntihistamines) are recommended as adjunctive therapy for atopic dermatitis (AD).

29 Ablation is a widely used therapy for atrial fibrillation (AF); however, arrhythmi

30 (Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [CABANA]; NCT00911

31 Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204

32 on-4 PAMAM dendrimer (D-Sino) as a potential therapy for attenuating early inflammation in TBI.

33 ng the timing and possible outcomes of human therapies for auditory dysfunction in ASD.

34 te Foxp3 could lead to more effective T(reg) therapies for autoimmune disease and cancer.

35 als hold great potential as an off-the-shelf therapy for biomedical application such as drug delivery

36 sociated signaling effectors may be a useful therapy for blocking tumor progression in patients with

37 rate nanoparticles into both diagnostics and therapy for both grafts ex-situ before transplantation a

38 rapy) and step 4 (medium-dose ICS-formoterol therapy) for both daily and as-needed therapy.

39 genic transcription factors has promise as a therapy for BPD in preterm infants.

40 iven the interest in developing TME-targeted therapies for brain malignancies, this comprehensive res

41 r richer array of PARP inhibitor combination therapies for BRCA1-deficient cancers than would be iden

42 or early breast cancer and adjuvant targeted therapy for breast cancer.

43 Prescription of guideline recommended therapies for CAD as well as clinical outcomes (emergenc

44 The first wave of genetically targeted therapies for cancer focused on drugging gene products t

45 ress has been made in the development of new therapies for cancer, dramatically changing the landscap

46 easingly important asset in developing novel therapies for cancer.

47 lied to optimize immune checkpoint inhibitor therapy for cancer treatment.

48 st protocols of adoptive cell transfer (ACT) therapy for cancer, but is limited by short exposure and

49 est that it may be possible to develop novel therapies for cardiovascular disease by selectively modu

50 toxumab in participants receiving antibiotic therapy for CDI.

51 and gluten-free dieting, the only available therapy for CeD.

52 mplications of this genetic relationship for therapies for CHD, for therapies for T2D, and for therap

53 This may be a viable preventative therapy for childhood asthma.

54 Targeted therapies for chronic lymphocytic leukemia (CLL) include

55 The only currently available therapy for chronic SND is the implantation of an electr

56 toward the development of novel, ecological therapies for controlling S. aureus carriage.

57 time, and the recommendations for switching therapies for convenience and for other reasons are incl

58 and rigorously assess potentially promising therapies for coronavirus disease 2019 (COVID-19); this

59 y attracted widespread interest as potential therapies for coronavirus disease 2019.

60 scent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19).

61 e is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19).

62 thors posit the need for rapid evaluation of therapies for COVID-19 as an inflection point spurring a

63 Furthermore, there are no approved therapies for COVID-19.

64 the immunological impacts of glucocorticoid therapy for COVID-19.

65 heir understanding could offer potential new therapies for CRSwNP (incurable disease).

66 n health will be key to developing effective therapies for dementia.

67 could be potentially used as a prophylactic therapy for diabetes and obesity, respectively.

68 g targets is critical to developing targeted therapies for diseases.

69 s nerve stimulation (VNS) is a bioelectronic therapy for disorders of the brain and peripheral organs

70 To explore and define therapies for DMD cardiomyopathy, the authors used DMD p

71 c compounds may be especially important as a therapy for dry AMD patients who have another common age

72 : To describe contemporary use of adjunctive therapies for early PARDS as a framework for future inve

73 he clinical use of antivirals as suppressive therapy for EBV lytic reactivation may aid efforts aimed

74 Monitoring before and during therapy for effectiveness and safety is recommended.

75 generation and may inform the development of therapies for enhancing intestinal repair after injury.

76 rovided valuable information about potential therapies for every tumor.

77 shion, so as to support tailoring of medical therapies, for example, in the context of liver disease

78 ther routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill wi

79 5 (+/-1 d) of microbiologically efficacious therapy for fermenting, gram-negative bacteria in blood

80 Several aspects of occupational therapy for FND are distinct from therapy for other neur

81 nts identified pyroxamide as a new potential therapy for FRMD6 deficient PC cells.

82 Surgery is the only effective therapy for ganglioneuroma, which may be challenging due

83 Current therapies for Gaucher disease include life-long intraven

84 ogels for clinical translation as an adjunct therapy for GBM treatment.

85 ristics associated with use of LT as primary therapy for glaucoma, including factors related to patie

86 UNDThe recent failure of checkpoint-blockade therapies for glioblastoma multiforme (GBM) in late-phas

87 nd dosing frequency of beta-Gal augmentation therapy for GM1 gangliosidosis.

88 Ideally, cellular therapy for GVHD will not affect alloreactive immune res

89 dosis, which could be targeted as adjunctive therapies for HAND-associated Alzheimer-like comorbidity

90 his phenomenon could inform immunomodulatory therapies for HBV cure.

91 rgeting Akt is being explored as a potential therapy for HCC.

92 With newer, direct-acting antiviral therapies for HCV, our objective was to determine whethe

93 RBV cotreatment with DAA-therapy for HCV increased CD56Bright NK cell IFNgamma-re

94 the development of epigenetic modulators as therapies for HD.

95 ts have been identified as a promising novel therapy for headache disorders.

96 Empiric antimicrobial therapy for healthcare-acquired infections often include

97 o clinical translation of cardiomyocyte cell therapies for heart disease.

98 mes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitra

99 mes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitra

100 mes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitra

101 mes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitra

102 mes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitra

103 The BeAT-HF (Baroreflex Activation Therapy for Heart Failure) trial was a multicenter, pros

104 t and Ventricular Remodeling During Entresto Therapy for Heart Failure).

105 Suggesting a potential therapy for hepatic IR, exogenous administration of buty

106 The effects of interferon-based therapies for hepatitis C virus (HCV) upon the risk of d

107 derstanding the arrhythmic behavior in novel therapies for HF.

108 ce as in clinical trials, PA pressure-guided therapy for HF was associated with lower PA pressures, l

109 Development of new therapies for HGSC has been hampered by a paucity of pre

110 lantation (alloSCT) is an important curative therapy for high-risk hematological malignancies, but th

111 function opens new avenues of study and even therapies for hippocampal dysfunction.

112 ritical problem limiting effective antiviral therapy for HIV/AIDS.

113 Frontline therapy for HLH consists of the glucocorticoid dexametha

114 ng of human memory that is needed to develop therapies for human memory disorders.

115 An effective therapy for human adenovirus (HAdV) infections in immuno

116 her evidence becomes available, device-based therapy for hypertension should not be considered for ro

117 e most extensively investigated device-based therapy for hypertension, and randomized, sham-controlle

118 Delayed side effects after radioiodine therapy for hyperthyroidism are hypothyroidism and a min

119 ctasis, severe hypoxemia, or need for rescue therapies for hypoxemia; and days with use of vasopresso

120 rther investigation as a clinically feasible therapy for ICH.

121 xploring inhibition of the MAPK pathway as a therapy for iMCD-TAFRO.

122 atients responded to anti-PD-1 or anti-PD-L1 therapy for immunotherapy-naive disease, and three (5.4%

123 igh-risk of progression, permitting targeted therapy for improved outcomes.

124 logy of this shock is unclear, and effective therapies for improving clinical outcomes are lacking.

125 oids, optic canal decompression, and medical therapy for indirect TON, the weight of published eviden

126 ytes opens an avenue for developing targeted therapy for INF2-mediated FSGS.

127 my balloon or to receive antiarrhythmic drug therapy for initial rhythm control.

128 ts derived from stem cells hold promise as a therapy for insulin-dependent diabetes, but there remain

129 ntravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasi

130 s the long-term effectiveness of combination therapy for intermittent claudication, compared with sup

131 es (phages) is proposed as a highly specific therapy for intestinal pathobiont elimination.

132 studies evaluating the impact of combination therapy for invasive MRSA infections.Patients treated wi

133 mal Cells (MSCs) are widely used in cellular therapy for joint repair.

134 egy may be efficient for delivering exercise therapies for knee osteoarthritis.

135 ld serve as an effective protein replacement therapy for LAMA2-CMD.

136 an serve as an effective protein-replacement therapy for LAMA2-CMD.

137 Gene therapy for Leber congenital amaurosis (LCA) is becoming

138 inical data consisting of patients receiving therapy for liver metastases.

139 n of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease.

140 Surgery is the primary therapy for localized chondrosarcoma; for locally advanc

141 al of 14 patients with relapse after initial therapy for low-risk disease (R1/R2) was 50 +/- 13% comp

142 g the possibility of developing immune-based therapies for lowering cardiovascular risk.

143 Evolocumab is an effective therapy for lowering atherogenic lipoproteins in PLHIV w

144 rone, lumacaftor, has been proposed as novel therapy for LQT2.

145 nd their regulation by CRT could lead to new therapies for lung and liver diseases linked to AAT defi

146 Many therapies for lysosomal storage disorders rely on cross-

147 ition of AQP3-mediated H(2)O(2) transport as therapy for macrophage-dependent liver injury.

148 This indicates that a MAb-based therapy for MACV could be effective.

149 al for Orai1 channel inhibitors as inotropic therapies for maintaining contractility reserve after hy

150 ablation is superior to antiarrhythmic drug therapy for maintaining sinus rhythm, but its success va

151 a partner drug of a single-dose combination therapy for malaria.

152 ture increasingly is accepted as a potential therapy for many diseases in the Western world.

153 py is becoming a key component of multimodal therapy for many stages of prostate cancer, particularly

154 Despite advances in therapy for melanoma, heterogeneous responses with limit

155 Curative therapy for metastatic cancers is equivalent to causing

156 prove the survival has become the first-line therapy for metastatic RCC patients.

157 ts who underwent immune checkpoint inhibitor therapy for metastatic skin cancer.

158 ovide the basis for promising novel systemic therapies for MFS and UPS.

159 away we are from the first FDA-approved drug therapy for mitochondrial disease.

160 ver therapy) is recommended as the preferred therapy for moderate persistent asthma in step 3 (low-do

161 treated with immunomodulator and/or biologic therapy for moderate to severe UC.

162 stered IL-17 inhibitors are highly effective therapy for moderate-to-severe disease.

163 s in a complex trial to test investigational therapies for moderately frequent molecular targets.

164 treated with (selective) immune suppressive therapies for MS.

165 help to guide the development of efficacious therapies for MS.

166 etil, is currently in development as an oral therapy for multidrug resistant and carbapenem-resistant

167 bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB).

168 Targeted therapies for multiple myeloma (MM) include the anti-CD3

169 excitability opens new avenues for improved therapy for muscle channelopathies and diseases of the n

170 While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist ob

171 peutic targets and characterizing novel drug therapies for NASH.

172 y independent of ATP and are now the primary therapy for neonatal diabetes mellitus caused by mutatio

173 lso provide potential prospects for new cell therapies for nervous system disorders and injury.

174 geted treatment and the development of novel therapies for neuropathic pain.

175 processing or to translate findings into new therapies for neuropathology.

176 nalized and more effective brain stimulation therapies for neuropsychiatric disorders.

177 omide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma.

178 isks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and b

179 unity, and open new avenues for T cell-based therapies for Nod2-associated disorders such as Blau syn

180 The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are dir

181 ately facilitating the identification of new therapies for numerous psychiatric disorders.

182 e FGFR1/KLB complex in humans can be used as therapy for obesity-related metabolic defects.

183 Current and potential medical therapy for obstruction-induced myopathic bladder dysfun

184 apomorphine sublingual film as an on-demand therapy for off episodes in patients with Parkinson's di

185 t the potential for developing PKCe-targeted therapies for oncogenic RAS-driven malignancies.

186 s to an expanding list of genomically driven therapies for oncogenic subsets of NSCLC.

187 dividual biological variations and precision therapies for oral health.

188 cupational therapy for FND are distinct from therapy for other neurological conditions.

189 e discuss NSC transplantation as a promising therapy for P-MS, elaborate on the necessities of clinic

190 the potential to be an effective neoadjuvant therapy for pancreatic cancer patients.

191 Main Results: We investigated six adjunctive therapies for PARDS: continuous neuromuscular blockade,

192 ptyline and trimipramine, could be potential therapies for Parkinson's disease.

193 exposed the inherent limitations of generic therapies for patient treatment.

194 y improved survival compared with historical therapies for patients with AT/RT.

195 timulate GBM repair could translate into new therapies for patients with GBM-associated disease.

196 rstanding of the potential of cytokine-based therapies for patients with MS.

197 etect VC activity in conjunction with future therapies for patients with mutations in the VC.

198 ted in the development of HIF2alpha-targeted therapies for patients with VHL-associated tumors.

199 The median duration of VV ECMO therapy for patients who have been decannulated is 12 da

200 coagulant medications are the cornerstone of therapy for patients with acute coronary syndrome and ha

201 FOLFIRINOX has become a standard therapy for patients with advanced PDAC and can be used

202 efficiency and overall quality of radiation therapy for patients with cancer.

203 Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus t

204 Multimodality therapy for patients with locally advanced esophageal ca

205 linexor (plus dexamethasone) as a fifth-line therapy for patients with multiple myeloma and as a mono

206 fective antifibrillatory, minimally invasive therapy for patients with potentially life-threatening a

207 oronary interventions in addition to medical therapy for patients with stable coronary artery disease

208 updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung c

209 n remains the standard of care for induction therapy for patients with standard-risk and intermediate

210 ocorticoids (GCs) are a central component of therapy for patients with T cell acute lymphoblastic leu

211 number of highly effective disease-modifying therapies for people with multiple sclerosis (MS) have r

212 relapse and to monitor efficacy of systemic therapies for personalised cancer patient management.

213 he efficacy of spoken language comprehension therapies for persons with aphasia remains equivocal.

214 Choice of empiric therapy for pneumonia depends on risk for antimicrobial

215 elop ALAS2 inhibitors as substrate reduction therapy for porphyria disorders that accumulate toxic he

216 Optimal upfront therapy for posttransplant lymphoproliferative disease (

217 ctive study, patients who underwent ablation therapy for presumed HCC followed by liver transplantati

218 hrony in these space-time events; therefore, therapies for prevention and treatment require fundament

219 tion for two randomisation factors (previous therapy for prevention of attacks and nature of the most

220 and composition of this pool are a target of therapies for primary biliary cholangitis and nonalcohol

221 One-by-one, gene therapy for primary immune deficiencies is being brought

222 tions from the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline were clear, thor

223 e released the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline.

224 this a key challenge for the development of therapies for proteinopathies.

225 esponse to the numerous current and emerging therapies for PsD, so that precision medicine can be app

226 ensity infections and may require additional therapy for radical cure.

227 Sorafenib should not be used as adjuvant therapy for RCC.

228 Referral from primary care to physical therapy for recent-onset sciatica improved disability an

229 cuity in both eyes following 3 months of PTX therapy for recurrent liver metastases.

230 State-of-the art therapy for recurrent ovarian cancer suitable for platin

231 cerns for the safety of PSC-derived cellular therapies for regenerative medicine.

232 used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term sup

233 The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma

234 till a challenge to develop gene replacement therapy for retinal disorders caused by mutations in lar

235 Currently, there is no therapy for reversing periodontal disease, and treatment

236 Nevertheless, the first attempts of gene therapy for SCID X1 were associated with insertional mut

237 sible and has the potential to guide medical therapy for secondary prevention.

238 tention has shifted towards more closed-loop therapies for seizure control, and on-demand optogenetic

239 Deep brain stimulation may be an effective therapy for select cases of severe, treatment-refractory

240 e in sepsis and could be targeted to develop therapies for sepsis.

241 rationale for trials of checkpoint inhibitor therapy for sepsis.

242 thiamine has been identified as a potential therapy for septic shock.

243 DAC inhibitors and regulators to improve the therapy for several disease states.

244 le experimental modalities to model and test therapies for severe neurodevelopmental disorders, while

245 epidermis after transplantation, a curative therapy for severe burns and, recently, diseases with ep

246 Notwithstanding the advent of this and other therapies for SMA, it is unclear whether the paralysis a

247 stroma can confer resistance to immune-based therapies for solid tumors and current advancements in s

248 designed to address an unmet need for better therapies for squamous non-small-cell lung cancer.

249 ed (NIR), has been identified as a promising therapy for stiffening pathologically weakened corneas.

250 and imaging studies, and early anticoagulant therapy for suspected pulmonary arterial thrombosis or t

251 etic relationship for therapies for CHD, for therapies for T2D, and for therapies that affect both.

252 l autophagy may contribute to development of therapies for tauopathies.

253 argeting S100A8/A9 pathways as host-directed therapy for TB.

254 of pravastatin as adjunctive, host-directed therapy for TB.

255 ent-derived stem cells, offering a promising therapy for telomere biology diseases.

256 The paucity of therapies for tendon injuries is due to our limited unde

257 ated TGNC and may be considered as cell-free therapy for TG nerve repair.

258 the development of established GLP-1R-based therapies for the long-term preservation of beta cell fu

259 ession, can lead to targeted and combination therapies for the treatment of this incurable disease.

260 he subthalamic nucleus (STN) is an effective therapy for the motor symptoms of Parkinson's disease (P

261 nt alone remained superior to interventional therapy for the prevention of death or symptomatic strok

262 pportunities for novel applications of CAR-T therapy for the treatment of both haematological maligna

263 ial of evoking memory response as a curative therapy for the treatment of CRC liver metastasis.

264 Despite the use of antiretroviral therapy for the treatment of HIV-1 infection, cognitive

265 ation and evaluation toward developing a new therapy for the treatment of MLL leukemia.

266 e at 80 mug/NmL, being a promising candidate therapy for the treatment of peri-implant diseases.

267 at the clinical and genetic levels, current therapies for these cancers fail to provide long-term cu

268 thelial growth factor (VEGF) has transformed therapy for these proliferative retinopathies.

269 nce so far to suggest possible approaches to therapy for these two diseases that could go beyond atte

270 V362, this work will enable testing of novel therapies for this aggressive form of ovarian cancer.

271 Considering the necessity of alternative therapies for this disease of high economic impact and t

272 us, there is a great need for more effective therapies for this illness.

273 There are no targeted therapies for this subset of lung cancers, nor is it kno

274 No proven effective therapies for this virus currently exist.

275 eration is elusive and there is currently no therapy for this blinding disorder.

276 Gene therapy for this disease presents inherent hurdles since

277 hara et al., holds the promise of a curative therapy for this disease.

278 mmunomodulatory drug combination maintenance therapy for this patient population.

279 To date, anticoagulant therapy for thrombosis at unusual sites is generally acc

280 ) and followed during the first 12 months of therapy for time to ADA development.

281 ding has the potential to open a new area of therapy for TNBC.

282 lly guide the development of neuromodulation therapies for Tourette syndrome that could use a closed-

283 s well as refine targets for neuromodulation therapies for Tourette syndrome.

284 izes current and prospective pharmacological therapies for treating both EDS and cataplexy, discusses

285 efforts to develop pharmacological and gene therapies for treating cocaine use disorders.

286 t and increased use of targeted radionuclide therapy for treating cancer comes the increased risk of

287 To develop a lytic-induction therapy for treating patients with EBV-associated cancer

288 may be helpful as part of a lytic-induction therapy for treating patients with EBV-positive malignan

289 m the development of novel anti-sncRNA-based therapies for treatment of VZV diseases.IMPORTANCE Varic

290 rived interneurons is a promising cell-based therapy for treatment of these disorders.

291 Preventive therapy for tuberculosis reduces the risk of disease in

292 Optimal immune-based therapies for type 1 diabetes (T1D) should restore self-

293 insulin delivery and insulin-producing cell therapies for type 1 diabetes management.

294 Islet transplantation is an emerging therapy for type 1 diabetes and hypoglycemic unawareness

295 Despite being the frontline therapy for type 2 diabetes, the mechanisms of action of

296 e co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and met

297 -specific T cell receptors (TCRs) are potent therapies for viral infections and cancer.

298 Switching therapy for virological failure is relatively rare at th

299 lonal tracking in patients treated with gene therapy for Wiskott-Aldrich syndrome (WAS) and beta-hemo

300 d assessed it in the context of risk-adapted therapy for young patients with NRSTS.